Kaiser Permanente brachytherapy Coverage Update

Coverage Criteria and Evidence Conclusions

APBI (brachytherapy as sole therapy) eligibility

Covered when ALL of the following are met:

APBI candidate: age: Age ≥ 50 (age 40–49 may be considered case-by-case)≥ 50 (case-by-case 40–49)

Invasive ductal cancer criteria: Diagnosis of unifocal invasive ductal carcinoma AND tumor size ≤ 3 cm AND negative surgical margins ≥ 2 mm AND negative nodal statustumor size ≤ 3 cm; margins ≥ 2 mm

DCIS alternative: Diagnosis of ductal carcinoma in situ (DCIS) meeting ALL of: detected on screening; low-to-intermediate nuclear grade; tumor size ≤ 2.5 cm; resected with margins negative at ≥ 3 mmtumor size ≤ 2.5 cm; margins ≥ 3 mm

Contraindications (exclusions): Not eligible if any of the following: age < 40; lobular histology; DCIS that does not meet the DCIS criteria above; extensive intraductal component (EIC); anatomic limitations; angiolymphatic space invasion

See policy exclusions for full list

APBI (breast) — insufficient evidence

Breast cancer — accelerated partial breast irradiation (APBI) and balloon-based/AccuBoost systems:

APBI evidence position: There is insufficient evidence to determine whether APBI delivered by balloon-based brachytherapy or AccuBoost is safe and provides non-inferior or superior local tumor control and survival compared to whole breast irradiation; available studies are largely phase I/II or nonrandomized and have methodological limitations; large RCTs are ongoing.insufficient evidence

Large phase 3 trials (NSABP/RTOG, RAPID, GEC-ESTRO) are ongoing and may change conclusions

In-stent restenosis — supported

Coronary artery (intravascular) brachytherapy for in-stent restenosis:

Coronary intravascular brachytherapy: Randomized trials (GAMMA-One, beta-WRIST, SCRIPPS, START) demonstrated reduced need for revascularization in patients with in-stent restenosis treated with intracoronary brachytherapy; the use meets Kaiser Permanente Medical Technology Assessment Criteria.meets criteria

Long-term safety data limited; potential acute vascular complications described

Endobronchial brachytherapy — insufficient evidence

Endobronchial brachytherapy for lung cancer:

Endobronchial brachytherapy efficacy: Randomized trials provide mixed results and the evidence is insufficient to fully determine the efficacy and safety of endobronchial brachytherapy (EBT) whether used alone or in addition to external beam radiation for NSCLC.insufficient evidence

Some RCTs showed benefit for symptom relief/atelectasis while others favored EBRT; trials limited by small size and other methodological issues

Prostate HDR brachytherapy — insufficient/limited evidence

High-dose-rate (HDR) brachytherapy for prostate cancer:

HDR brachytherapy monotherapy: There is insufficient evidence to draw conclusions about effectiveness and safety of HDR brachytherapy as monotherapy compared with accepted treatments for prostate cancer (no randomized trials).insufficient evidence

Available data are case series or nonrandomized

HDR brachytherapy plus EBRT: Some studies, including a randomized trial and nonrandomized comparisons, suggest improved biochemical control when HDR brachytherapy is added to EBRT, but evidence is limited and insufficient to demonstrate improvements in disease-specific or overall survival; adverse effects data are limited.limited evidence

Trials underpowered for survival outcomes; toxicity reporting incomplete

Gynecologic brachytherapy — practice context and background

Gynecologic (cervical/endometrial) brachytherapy — background

Gynecologic brachytherapy use: Intracavitary brachytherapy combined with EBRT is standard for cervical cancer; intravaginal brachytherapy is commonly used for endometrial cancer to reduce vaginal apex recurrence after hysterectomy. HDR and LDR modalities have differing operational profiles and trade-offs.established practice

HDR generally accepted at dose rates 50–500 cGy/min; optimal fractionation and long-term complications not fully standardized

Site-specific evidence conclusions / coverage stance

Coverage stance varies by cancer site and available evidence; where criteria in applicable policy statements are met, listed CPT/HCPCS codes are considered medically necessary.

HDR prostate brachytherapy: Insufficient evidence to determine whether HDR brachytherapy alone or with EBRT is safe and effective for prostate cancer

Studies lacked randomized controlled trials or had methodological limitations

HDR vs LDR for cervical cancer: Trials generally did not find statistically significant differences in survival or adverse effects between HDR and LDR for cervical cancer but were not designed as equivalence studies; evidence does not meet assessment criteria for definitive conclusions

Potential design flaws and limited power in RCTs

HDR vs LDR for endometrial cancer: No studies identified that specifically compare HDR and LDR for endometrial cancer; insufficient evidence to support a conclusion

Evidence gap noted

Procedure code coverage when clinical criteria met

Considered medically necessary when criteria in the applicable policy statements listed above are met.

Procedure-level necessity: The CPT and HCPCS codes listed in this policy are considered medically necessary when the site-specific clinical criteria in this policy are satisfied.

Verify authorization requirements per member plan via the Pre-authorization Code Check

Contraindications and situations where brachytherapy is not appropriate are specified for breast applications and more broadly. For accelerated partial breast irradiation (APBI) as a sole therapy the policy requires Age ≥ 50 (patients age <40 are contraindicated, and ages 40–49 may be considered only case-by-case), and tumor-specific limits (for invasive ductal disease: unifocal, tumor size ≤ 3 cm, negative margins ≥ 2 mm, and negative nodes; for DCIS: screen-detected, low–intermediate grade, tumor size ≤ 2.5 cm, margins ≥ 3 mm). The policy lists additional exclusions including lobular histology, DCIS that does not meet the stated criteria, extensive intraductal component (EIC), anatomic limitations, and angiolymphatic space invasion.

The policy notes specific contexts where adjunctive or boost uses and certain anatomic-site applications lack sufficient evidence to meet assessment criteria. Historically, brachytherapy used as an adjunct/boost to whole-breast radiation (including balloon-based devices and AccuBoost) did not meet MTAC criteria. Likewise, endobronchial brachytherapy for lung cancer is identified as an application with mixed trial results and insufficient evidence to support routine use, and the policy highlights that some brachytherapy uses are considered routine only when supported by clinical criteria and recommendation from the treating practitioner.

The document identifies several applications where the evidence is insufficient to establish safety and effectiveness. High-dose-rate (HDR) brachytherapy for prostate cancer—whether as monotherapy or combined with EBRT—lacks randomized trial data and is concluded to have insufficient evidence. Comparisons of HDR versus LDR brachytherapy for cervical and endometrial cancer are limited or absent; cervical trials were underpowered or not designed as equivalence studies, and there are no studies specifically comparing HDR and LDR for endometrial cancer. Use of radioactive seeds for recurrent high-grade glioblastoma is supported only by case series and therefore also represents an evidence gap.

Historical MTAC assessments for breast cancer brachytherapy found that studies of brachytherapy as either an adjunct/boost or as sole therapy were methodologically limited — many were nonrandomized, underpowered, or used historical controls. MTAC concluded that the available studies were not designed to demonstrate equivalence to whole-breast external beam radiation, and therefore did not meet Kaiser Permanente Medical Technology Assessment Criteria.

Because multiple indications reviewed did not meet MTAC criteria, the policy makes clear that such indications may be considered not medically necessary for routine coverage or may require additional justification. Procedures lacking MTAC support (for example, adjuvant balloon-based APBI/AccuBoost, routine endobronchial brachytherapy, or routine HDR prostate monotherapy) are at higher risk for coverage denials and may need case-by-case review or enrollment in clinical trials to be considered.

The policy explicitly calls out specific applications judged to have inadequate evidence: HDR prostate brachytherapy (monotherapy or in combination with EBRT) lacks RCT data and does not meet MTAC; there are no adequate comparative studies of HDR versus LDR brachytherapy for endometrial cancer; and brachytherapy (radioactive seed implants) for recurrent high‑grade glioblastoma is supported only by case series and is insufficient to establish efficacy or safety.

Procedure and Billing Codes

Covered procedures (described)mixedCovered

not specified

Standard brachytherapy is covered without medical necessity review for coronary artery (intravascular) brachytherapy; endobronchial brachytherapy (lung cancer); high-dose or low-dose brachytherapy for cervical and endometrial cancer; and prostate cancer (HDR/LDR) per policy statements.

Insufficient evidence / experimentalmixedExperimental

not specified

Radioactive seeds for treatment of recurrent high-grade glioblastoma — insufficient evidence to show safety or improved long-term outcomes compared with standard therapies.

Devices/modalities referencedmixed

MammoSite, Axxent, Contura, AccuBoost

Device/modalities mentioned for accelerated partial breast irradiation (APBI) and electronic brachytherapy in the narrative.

Considered medically necessary CPT/HCPCS codes when criteria metmixedCovered

19296	Placement of radiotherapy afterloading expandable catheter (single or multichannel) into the breast for interstitial radioelement application following partial mastectomy, includes imaging guidance; on date separate from partial mastectomy.
19297	Placement of radiotherapy afterloading expandable catheter (single or multichannel) into the breast for interstitial radioelement application following partial mastectomy, includes imaging guidance; concurrent with partial mastectomy (List separately in addition to code for primary procedure).
19298	Placement of radiotherapy after loading brachytherapy catheters (multiple tube and button type) into the breast for interstitial radioelement application following (at the time of or subsequent to) partial mastectomy, includes imaging guidance.
20555	Placement of needles or catheters into muscle and/or soft tissue for subsequent interstitial radioelement application (at the time of or subsequent to the procedure).
31643	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with placement of catheter(s) for intracavitary radioelement application.
41019	Placement of needles, catheters, or other device(s) into the head and/or neck region (percutaneous, transoral, or transnasal) for subsequent interstitial radioelement application.
58346	Insertion of Heyman capsules for clinical brachytherapy.
61770	Stereotactic localization, including burr hole(s), with insertion of catheter(s) or probe(s) for placement of radiation source.
76965	Ultrasonic guidance for interstitial radioelement application.
77316	Brachytherapy isodose plan; simple (calculation(s) made from 1 to 4 sources, or remote afterloading brachytherapy, 1 channel), includes basic dosimetry calculation(s).

1–10 of 25

1/3

MammoSite dosing — typical fractionation schedule

Typical MammoSite regimen34 Gy in 10 fractions (3.4 Gy per fraction delivered twice daily with a minimum 6 hours between fractions)

Indicated tumor sizePrimary tumors with diameter < 3 cm commonly recommended for MammoSite

Common patient selection notesMay be used for DCIS and invasive ductal carcinoma; not suitable for small breasts or tumors with inadequate skin-to-cavity distance

HDR dose rate typical range

Typical HDR dose-rate range50-500 cGy/minute

Dose delivery characteristic

Authorization, Documentation, and Process

Note

Medical necessity review / Coverage without review

Medical necessity review / coverage without review: Some brachytherapy services (for example, standard brachytherapy for prostate, cervical, endometrial cancer, endobronchial, and intravascular coronary brachytherapy) are covered without a medical necessity review when they meet the applicable policy criteria. For other indications, including many applications of accelerated partial breast irradiation (APBI) and high-dose-rate (HDR) prostate brachytherapy, medical necessity review is required. Retired Local Coverage Determinations (LCDs) may inform initial decisions but cannot be cited on appeal; reviewers (e.g., Maximus) may apply medical judgment and reference commercial criteria or literature searches.

Covered without review: select standard brachytherapy indications (see policy criteria).
Require review: indications not meeting standard covered criteria, APBI in many settings, HDR prostate brachytherapy depending on indication.

Prior Authorization

Prior authorization recommended for APBI and HDR prostate brachytherapy

Prior authorization recommended for APBI and HDR prostate brachytherapy: Because evidence for APBI and HDR prostate brachytherapy is limited and these services may be considered investigational or require demonstration of specific criteria, prior authorization is recommended to confirm medical necessity and appropriate patient selection.

Background and Scope

Brachytherapy (internal radiation) delivers a high radiation dose directly to the tumor or tumor cavity by placing radioactive material inside or adjacent to the target. Delivery methods include temporary source afterloading (commonly high-dose-rate, HDR, using sources such as iridium-192, delivered in short outpatient fractions at dose rates generally between 50–500 cGy/minute), and permanent seed implantation (low-dose-rate, LDR) in which radioactive seeds remain in place and radioactivity decays over time. Common clinical applications include prostate seed implantation, intracavitary brachytherapy for cervical cancer, and intracavitary or intracavitary‑based accelerated partial breast irradiation targeted to the lumpectomy cavity plus margin.

Key Definitions

Definition — APBI (accelerated partial breast irradiation) key features and delivery

DefinitionAccelerated partial breast irradiation (APBI) is radiation limited to the lumpectomy bed plus a 1–2 cm margin delivered in a shortened schedule (typically ≤1 week) using techniques such as interstitial multicatheter brachytherapy, balloon catheter devices (e.g., MammoSite, Contura), electronic brachytherapy (Xoft Axxent), or AccuBoost image-guided applicators)

PurposeReduce treatment volume and duration compared with whole-breast external beam radiation while targeting the surgical cavity

Delivery methodsInterstitial multicatheter, balloon-based intracavitary devices, electronic brachytherapy, and image-guided peripheral applicators (AccuBoost)

Definition — Permanent brachytherapy (seed implantation)

DefinitionPermanent brachytherapy (seed implantation) involves placing radioactive seeds or pellets (about the size of a grain of rice) in or near the tumor and leaving them in place; radioactivity gradually diminishes over weeks to months

Policy Revision History

1998policy_origin

Initial policy created (original review recorded in 1998).

2002-06-12MTAC review

MTAC review of breast cancer brachytherapy with evidence conclusion regarding equivalence to whole breast radiation noted.

2007-10-01MTAC review

MTAC review of high-dose-rate (HDR) brachytherapy for prostate cancer concluded insufficient evidence for HDR monotherapy.

OpenPayer

Clinical Review Criteria — Brachytherapy